Last reviewed · How we verify

Daratumumab with dexamethasone

Hellenic Society of Hematology · Phase 2 active Small molecule

Daratumumab with dexamethasone is a Monoclonal antibody Small molecule drug developed by Hellenic Society of Hematology. It is currently in Phase 2 development for Multiple myeloma. Also known as: DaraD, Darzalex, Dara, Dex.

Daratumumab is a monoclonal antibody that targets CD38, a protein found on the surface of multiple myeloma cells.

Daratumumab is a monoclonal antibody that targets CD38, a protein found on the surface of multiple myeloma cells. Used for Multiple myeloma.

At a glance

Generic nameDaratumumab with dexamethasone
Also known asDaraD, Darzalex, Dara, Dex
SponsorHellenic Society of Hematology
Drug classMonoclonal antibody
TargetCD38
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

By binding to CD38, daratumumab triggers the destruction of these cancer cells. This mechanism is thought to be responsible for the therapeutic effects of daratumumab in multiple myeloma. The addition of dexamethasone, a corticosteroid, is believed to enhance the efficacy of daratumumab by modulating the immune response and reducing inflammation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Daratumumab with dexamethasone

What is Daratumumab with dexamethasone?

Daratumumab with dexamethasone is a Monoclonal antibody drug developed by Hellenic Society of Hematology, indicated for Multiple myeloma.

How does Daratumumab with dexamethasone work?

Daratumumab is a monoclonal antibody that targets CD38, a protein found on the surface of multiple myeloma cells.

What is Daratumumab with dexamethasone used for?

Daratumumab with dexamethasone is indicated for Multiple myeloma.

Who makes Daratumumab with dexamethasone?

Daratumumab with dexamethasone is developed by Hellenic Society of Hematology (see full Hellenic Society of Hematology pipeline at /company/hellenic-society-of-hematology).

Is Daratumumab with dexamethasone also known as anything else?

Daratumumab with dexamethasone is also known as DaraD, Darzalex, Dara, Dex.

What drug class is Daratumumab with dexamethasone in?

Daratumumab with dexamethasone belongs to the Monoclonal antibody class. See all Monoclonal antibody drugs at /class/monoclonal-antibody.

What development phase is Daratumumab with dexamethasone in?

Daratumumab with dexamethasone is in Phase 2.

What are the side effects of Daratumumab with dexamethasone?

Common side effects of Daratumumab with dexamethasone include Fatigue, Nausea, Diarrhea, Thrombocytopenia, Anemia.

What does Daratumumab with dexamethasone target?

Daratumumab with dexamethasone targets CD38 and is a Monoclonal antibody.

Related